Table 3.
Comparison of Tumor Subtype Between Primary and Recurrent Tumors
| HR, HER2 Status in Metastasis Sites | Total | ||||||
|---|---|---|---|---|---|---|---|
| HR+/HER2- | HR+/HER2+ | HR−/HER2+ | HR−/HER2- | HR−/HER2 Not Sure | HR+/HER2 Not Sure | ||
| HR, HER2 status in primary sites | |||||||
| HR+/HER2− | 77(28.5) | 11(4.1) | 2(0.7) | 15(5.6) | 5(1.9) | 21(7.8) | 131(48.5) |
| HR+/HER2+ | 5(1.9) | 32(11.9) | 10(3.7) | 2(2.9) | 2(2.9) | 10(3.7) | 61(22.6) |
| HR-/HER2+ | 0(0) | 5(1.9) | 16(6) | 5(1.9) | 4(1.5) | 6(2.2) | 36(13.3) |
| HR-/HER2− | 13(4.8) | 3(1.1) | 4(1.5) | 20(7.4) | 2(0.7) | 0(0) | 42(15.5) |
| Total | 95(35.2) | 51(18.9) | 32(11.9) | 42(15.6) | 13(4.8) | 37(13.7) | 270 |
Note: −, Means receptor expression negative; +, Means receptor expression positive.
Abbreviations: HER2, human epidermal growth factor receptor 2; HR, hormone receptor.